SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (NASDAQ: JAGX) and Elanco US Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), today announced an agreement (the “Agreement”) to ...

Company Prepares for New Prescription Drug Launch in First Half of 2016 for Dogs Suffering from Chemotherapy-Induced Diarrhea SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (NASDAQ: JAGX) ...

SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for ...

SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...

Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO, ...

Company's Canalevia ®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive ...

San Francisco, CA (July 7, 2015): Jaguar Animal Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), an animal health company focused on developing and commercializing first-in-class ...

An update from Jaguar Animal Health ( ($JAGX) ) is now available. On November 12, 2025, Jaguar Health, Inc. entered into a note purchase agreement ...

Jaguar Animal Health, Inc. (JAGX) ("Jaguar" or the "Company"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production ...

SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...